Biomarkers of Systemic Inflammation and Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial
Open Access
- 8 February 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 171 (5), 571-582
- https://doi.org/10.1093/aje/kwp406
Abstract
The authors conducted a nested case-control study of serum inflammatory markers and risk of symptomatic benign prostatic hyperplasia (BPH), using data from the placebo arm of the Prostate Cancer Prevention Trial (1993–2003). Incident BPH (n = 676) was defined as treatment, report of 2 International Prostate Symptom Score (IPSS) values >14, or 2 increases of ≥5 from baseline values with at least one value ≥12. Controls (n = 683) were men who reported no BPH treatment or IPSS values >7 over the 7-year trial. Baseline serum was analyzed for C-reactive protein, tumor necrosis factor α (monomer), soluble tumor necrosis factor receptors I and II (sTNF-RI and sTNF-RII), interleukin 6, and interferon γ. Controlled for age and race, a high C-reactive protein concentration was associated with increased BPH risk (for quartile 4 vs. quartile 1, odds ratio (OR) = 1.40, 95% confidence interval (CI): 1.04, 1.88); this was attenuated after control for body mass index (OR = 1.30, 95% CI: 0.95, 1.75). Low sTNF-RII and high interleukin 6 concentrations were associated with increased BPH risk (for quartile 4 vs. quartile 1, sTNF-RII: OR = 0.61, 95% CI: 0.46, 0.82; interleukin 6: OR = 1.79, 95% CI: 1.32, 2.42); these associations were only in men aged <65 years. Results suggest that systemic inflammation or lower levels of soluble receptors that bind inflammatory cytokines increase BPH risk.Keywords
This publication has 49 references indexed in Scilit:
- Associations Between C-Reactive Protein and Benign Prostatic Hyperplasia/Lower Urinary Tract Symptom Outcomes in a Population-based CohortAmerican Journal of Epidemiology, 2009
- Serum Steroid and Sex Hormone-Binding Globulin Concentrations and the Risk of Incident Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention TrialAmerican Journal of Epidemiology, 2008
- Insulin‐like growth factor‐I, insulin‐like growth factor binding protein‐3 and risk of benign prostate hyperplasia in the prostate cancer prevention trialThe Prostate, 2008
- The Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE TrialEuropean Urology, 2007
- Inflammation in prostate carcinogenesisNature Reviews Cancer, 2007
- Chronic bacterial infection and inflammation incite reactive hyperplasia in a mouse model of chronic prostatitisThe Prostate, 2006
- Prevalence of conditions potentially associated with lower urinary tract symptoms in menBJU International, 2005
- The economics of benign prostatic hyperplasia treatment: a literature reviewClinical Therapeutics, 1996
- The potential biological and clinical significance of the soluble tumor necrosis factor receptorsCytokine & Growth Factor Reviews, 1996
- Two tumour necrosis factor receptors: structure and functionTrends in Cell Biology, 1995